🇺🇸

Corporate Governance

US SEC Filing Intelligence · 493 digests

New to these filings? Learn what a DEF 14A proxy statement is

· daily

US Executive Compensation Proxy SEC Filings — October 30, 2026

The 12 DEF 14A filings from October 30, 2026 reveal a broad market focus on governance, executive compensation, and strategic pivots, with several companies undergoing significant structural changes. Key themes include the termination of external management agreements (Cannae), merger-driven control shifts (Chemomab/Scipher), and charter amendments that could dilute common shareholders (Marwynn, Medicus). Executive compensation practices vary widely, from Tamboran's 35% increase in director fee pool to Stone Point's fee reduction contingent on proposal approvals. Insider ownership is highly concentrated in some cases (OpGen: 80.79% by directors/officers), raising governance concerns. Overall, filings are mostly routine but contain actionable insights for investors regarding upcoming votes, potential dilution, and strategic redirections.

12 high priority 12 total filings
· daily

US Executive Officer Management Changes SEC — October 30, 2026

A dense cluster of 34 officer/director filings on 2026-10-30 reveals a market in active leadership transition: at least 14 C-suite or board departures versus 12 appointments, with a striking concentration of interim/consultant CFO arrangements (Verra Mobility, PodcastOne/LiveOne, GridAI, Tempest) signaling thin finance benches at smaller caps. The most consequential events are deal-contingent: Utz Brands' CEO Howard Friedman exits November 30 only if the Intersnack take-private closes (special meeting November 13), and NextCure's CMO termination is explicitly tied to its Avere merger. Two genuine governance shocks stand out: Visium Technologies' CEO resigned citing doubts over a decade of financials (FY2016-FY2026) while the company disavowed his auditor certificate, and LiveOne/PodcastOne lost a single executive holding four roles simultaneously. Planned successions at Genworth (CEO McInerney to retire December 31, Upton to CEO) and Equity LifeStyle (Nader to Executive Vice Chair, Waite to CEO January 1) are orderly and low-risk, while Cable One's appointment of a restructuring veteran to a strategic-alternatives committee is a quiet but material signal. Financial disclosures mixed into the batch show Carter's margin expansion (+91.7% GAAP operating income) offset by a guidance cut to $3.05-$3.23 EPS, and ChoiceOne's flat Q3 EPS masked by merger-cost comps.

34 high priority 34 total filings
· daily

US Corporate Board Director Changes SEC Filings — October 30, 2026

This digest covers 33 SEC filings from October 30, 2026, with a heavy concentration of C-suite and board changes. Key themes include CEO successions at Genworth, Equity LifeStyle, and Utz Brands; CFO turnover at PodcastOne/LiveOne, Tempest Therapeutics, Verra Mobility, and GridAI; and board reshuffles at CIM Real Estate, Preformed Line Products, and Consumers Bancorp. Notable risks include the abrupt resignation of Visium Technologies' Chairman/CEO amid financial restatement disagreements, the departure of LiveOne's interim CFO leaving four roles vacant, and Utz Brands' CEO exit tied to a take-private merger. Positive signals include internal promotions at Ingersoll Rand and Gorman-Rupp, and performance-based equity grants at Omeros and Jaguar Uranium. The filings also reveal governance changes at LendingTree and Security Midwest Bancorp, and a strategic board appointment at Cable One to evaluate strategic alternatives.

33 high priority 33 total filings
· daily

US Executive Compensation Proxy SEC Filings — October 29, 2026

The 11 DEF 14A filings reveal a stark divide between large-cap stability and micro-cap distress, with governance actions often serving as distress signals. Cisco stands out with record FY2026 revenue of $63.3B (+12% YoY) and GAAP EPS up 31%, yet its non-GAAP operating margin expanded only 40 bps, highlighting earnings quality concerns. Meanwhile, five micro-cap companies (Vivos, Kindly MD, Ocean Power, Owens & Minor, Fly-E) are pursuing reverse splits or highly dilutive financings to address listing deficiencies or liquidity crunches, with potential dilution ranging from 25.9% to over 1,500% of current shares. A common theme is the use of equity incentive plan expansions (Vivos, Bonk, enVVeno) to preserve cash, often accompanied by significant share reserve increases (Bonk +70.3%). Insider control is pronounced at VASO (42.06% insider voting power) and Ocean Power (investors could hold 25.9% post-conversion), raising governance risks. Upcoming meetings cluster in December 2026, with key catalysts including reverse split approvals (Owens & Minor Dec 1, Vivos Dec 2) and say-on-pay votes (Cisco, Guidewire, enVVeno) that could signal shareholder unrest.

11 high priority 11 total filings
· daily

US Executive Officer Management Changes SEC — October 29, 2026

The October 29, 2026 filing batch is dominated by executive and board turnover, with 44 filings spanning CFO successions, CEO appointments, director additions and retirements. Key CFO transitions include Norwegian Cruise Line (Kempa to Montana, effective Jan 1, 2027), Strategy Inc (Kang out Nov 5, Virasteh in Jan 1, 2027), Summit Hotel (Nieves in Nov 1), Southern Missouri Bancorp (Chkautovich out Nov 7, Funke interim), and PennyMac (Ryan in Jan 1, 2027). CEO changes include Clorox (Fabian Garcia effective Jan 5, 2027, replacing Linda Rendle for health reasons), Estrella Immunopharma (Cynthia Pussinen, Oct 25), Shutterstock (founder Jon Oringer returns as CEO, Oct 28), and Hormel (Ghingo assumes CEO role, Oct 26). Board refreshment is broad, with 15+ director appointments across sectors, including several high-profile additions: Meta's former VP of Infrastructure to Aehr Test, former Fluor CEO to Marathon Petroleum, and former Cigna Chief Health Officer to Teva. Financial disclosures in the batch show mixed performance: Monolithic Power Systems posted record Q3 revenue of $1.2B (+63% YoY) and raised Q4 guidance, while BCB Bancorp reported a $132.5M quarterly loss and a $115M credit provision, and Bright Horizons swung to a $230.7M net loss on $294M impairment. Insider activity is limited but notable: CEO/CFO option grants at Ionetix and a voluntary salary cut by Coastal Financial's CEO. Overall, the batch signals a wave of leadership transitions that could drive strategic shifts, with several companies facing financial stress and others capitalizing on growth opportunities.

44 high priority 44 total filings
· daily

US Corporate Board Director Changes SEC Filings — October 29, 2026

The October 29, 2026 board-room batch is dominated by orderly C-suite successions and board refreshes rather than abrupt departures: 12+ officer changes and 15+ director appointments/resignations were disclosed, with most companies explicitly stating no disagreements. A clear succession wave is forming for early 2027 — Clorox (CEO Jan 5), NCLH (CFO Jan 1), PennyMac (CFO Jan 1), Strategy Inc (CFO Jan 1), Lionsgate (CFO term ends Jan 31), Forestar (Exec Chair Nov 1) — creating a catalyst calendar concentrated in Q4 2026–Q1 2027. Financial disclosures in the batch show a sharp bifurcation: AI/data-center semiconductor demand is booming (Monolithic Power revenue +63.1% YoY, first $1B quarter; Aehr adding Meta infrastructure expertise), while consumer/industrial names show margin pressure (Harley-Davidson HDMC revenue -10%, operating income -18%; Floor & Decor comps -1.4%; Saia operating ratio widened 170 bps). Governance stress is visible in several names: BCB Bancorp posted a $132.5M quarterly loss with a $115M credit provision and C-suite reorganization; Strategy Inc's CFO exit coincides with negative BTC Yield of (3.7)% and a $(2.03)B BTC loss; Shutterstock cancelled its Q3 earnings call amid a strategic review while reinstalling its founder as CEO. Insider/compensation signals skew toward alignment: Coastal Financial's CEO voluntarily cut his salary from $874K to $500K, while Ionetix and Estrella used equity-heavy, milestone-based pay to conserve cash.

44 high priority 44 total filings
· daily

US Executive Compensation Proxy SEC Filings — October 28, 2026

This digest covers 11 DEF 14A and DEFM14A filings in the Executive Compensation Insights stream, all dated around October 28, 2026. The filings are overwhelmingly procedural: most contain no quantified financial results, so period-over-period comparisons (YoY/QoQ) are unavailable for nearly every company, and the enriched data is largely limited to governance, voting mechanics, and meeting logistics. The most material development is Distribution Solutions Group's going-private merger led by CEO J. Bryan King, which carries a 9/10 materiality score, a December 31, 2026 outside date, a dual-majority disinterested-stockholder vote requirement, and roughly $189 million in recent acquisitions funded partly through the revolver. Governance themes recur across the set: plurality director elections, advisory say-on-pay and say-on-frequency votes, and leadership transitions (NAPCO's CEO and Executive Chairman changes, IBEX's chairman transition and Lead Independent Director appointment, Bridgeway's fund complex migration to RBB). A notable procedural signal is CEA Industries/BNB Standard's failed equity plan vote under the former bylaw standard, which treated abstentions and broker non-votes as against, underscoring how voting mechanics can defeat shareholder-supported proposals. Executive compensation disclosure is thin in the excerpts provided, with NAPCO the only filing disclosing compensation-governance details, and no insider transaction or capital allocation data was present in the enriched fields for these filings.

11 high priority 11 total filings
· daily

US Executive Officer Management Changes SEC — October 28, 2026

Across the 35 filings in this Officer and Director Change stream, leadership turnover is the dominant theme, with CEO, CFO, COO and CAO transitions at GE HealthCare's PCS unit, Enanta, Parsons, Q2 Holdings, Align Technology, LENZ Therapeutics, Monroe Federal, Dropbox, ABM and Compass Minerals, alongside a steady flow of board appointments and departures. The strongest reported operating performance came from HF Sinclair (Q3 net income $2,015M vs $403M, adjusted refinery gross margin $54.22/bbl vs $19.16) and GE HealthCare (Adjusted EBIT margin up 180 bps to 16.6%, guidance raised), while Etsy showed accelerating GMS growth (+8.8% Y/Y) and Nextpower posted record revenue (+22.5% Y/Y). Credit and profitability stress is visible at Regional Management (net credit loss rate up 70 bps to 10.9%, 30+ day delinquencies up 50 bps to 7.5%) and LENZ Therapeutics (net loss widened to $31.0M from $16.7M, with a targeted 50%+ cut to 2027 operating expenses). Several filings explicitly state departures were not due to disagreements, which lowers governance-alarm readings for those names. Watch-worthy governance items include the CEO transitions at Align (Davis effective December 31, 2026) and Enanta, and the interim CFO roles at Parsons and Q2 Holdings.

35 high priority 35 total filings
· daily

US Corporate Board Director Changes SEC Filings — October 28, 2026

Across the 35 filings, the dominant theme is leadership transition at the executive and board level, with CEO, CFO, COO, CAO and CTO changes concentrated in the 27 newly published filings. Several companies are restructuring leadership alongside operational shifts: LENZ Therapeutics is replacing its CEO as it cuts projected 2027 opex by more than 50%, Align Technology is installing a new CEO effective December 31, 2026, and Q2 Holdings and Parsons are using interim or dual-role CFO arrangements. Operating results are mixed rather than uniformly positive: HF Sinclair posted a sharp refining-driven earnings surge (Q3 net income of $2,015M vs $403M), Etsy and GE HealthCare showed accelerating top-line growth and margin expansion, while Nextpower saw gross margin fall 4.8 points sequentially despite record revenue, and Regional Management reported rising credit losses (+70 bps YoY to 10.9%). Board-composition changes skew toward independent and industry-experienced appointees (Gevo, ManpowerGroup, Arcutis, Vir, Churchill Downs), while several resignations (Garrett Motion, Bausch + Lomb, T-Mobile's Sievert, Red Robin) signal routine or negotiated exits rather than governance disputes, as each filing states no disagreement. Portfolio-level implication: leadership churn is elevated, so investors should weigh management continuity as a risk factor alongside reported financial momentum.

35 high priority 35 total filings
· daily

US Executive Compensation Proxy SEC Filings — October 27, 2026

This batch of 23 DEF 14A filings for the 2026-10-27 window is dominated by governance and shareholder-vote mechanics rather than compensation design: most proxies are routine (director elections, auditor ratification, say-on-pay) or capital-structure items (reverse splits, share authorizations, Yorkville financings, blank-check extensions). The most material situations are Mistras Group's $20.35/share cash take-private, Impact Biomedical's reverse-merger with Zoar (pending NYSE Amex listing and a July 1, 2026 outside date), VisionWave's dilution-heavy special meeting with the stock at $3.72 versus Yorkville floor prices, and Palo Alto Networks' strong fiscal 2026 growth ($11.48B revenue, up 24%; NGS ARR $9.10B, up 63%; RPO $21.2B, up 34%) absorbing the CyberArk acquisition. Among filings that disclose period-over-period figures, the picture is mixed: Stride reported net income up more than 17% and Adjusted EBITDA up more than 8%, SES AI showed Q2 revenue up over 40% YoY but down roughly 24% sequentially, and Armlogi's revenue fell 2.4% while its net loss widened 36.6%. Many proxies (Cimpress, KULR, PGIM ETF Trust, Oil-Dri, Fatpipe, Precision Optics, Galaxy Gaming) contain no financial results, so enriched period comparisons and insider-trading data are largely unavailable for them. Governance concerns recur across the set, including concentrated or super-voting control (HWH International at ~94.8% controlled, SES AI Class B shares at 10 votes, KULR Series A at 100 votes per share), combined CEO/Chair roles without a lead director, and auditor transitions (Marcum resignations at La Rosa and KULR, Grassi to HTL at HWH).

23 high priority 23 total filings
· daily

US Executive Officer Management Changes SEC — October 27, 2026

Across the 38 filings for the USA Executive & Director Changes stream (period 2026-10-27), the dominant theme is CFO and senior finance leadership turnover, with at least eight finance-chief transitions or interim appointments (Visteon, Goodyear, Axcelis, Hycroft, Visteon-linked Goodyear hire, Lifeward, TV Channels Network, Resources Connection) and several accounting-officer reshuffles at Ares-affiliated funds. Board refreshment is the second theme, with new independent directors added at Amgen, Better Home & Finance, Altimmune, Entera Bio, BlackBerry, Cooper Companies, Hycroft and Ares-related vehicles, often paired with director resignations or retirements. Most filings state no disagreement with operations, policies or practices, which lowers the probability of hidden governance conflict, though Cooper Companies' CEO exit alongside a reaffirmed guidance that 'has not met management's expectations' is the clearest governance-stress event. Period-over-period financial data is largely absent from these governance-focused 8-Ks, so the quantitative read-through is concentrated in Xylem (orders +7% reported, revenue -3%, FY guidance cut) and Cooper Companies. Market implication: finance-function continuity risk is elevated for several mid-caps during Q4 close and 2027 planning, and investors should track interim-to-permanent CFO timelines and any further CEO/board changes at Cooper.

38 high priority 38 total filings
· daily

US Corporate Board Director Changes SEC Filings — October 27, 2026

This digest covers 38 filings tied to the USA Board Room Changes stream (Officer Change, Director Change, Board Change), dated October 27, 2026. The dominant theme is C-suite and finance-leadership turnover: at least a dozen CFO, CAO, COO, CCO or CEO transitions, with several interim CFO appointments (Visteon, Axcelis, TV Channels, Resources Connection, Hycroft's planned transition) that point to near-term execution risk during reporting cycles. Board refreshment is equally visible, with new independent directors at Amgen, Better Home & Finance, Entera Bio, Altimmune, BlackBerry, Hycroft and FHLB Indianapolis, generally read as governance hygiene rather than distress. The most material event is Cooper Companies, where the CEO was removed and an independent director installed as Executive Chair while guidance was reaffirmed despite acknowledged underperformance. Xylem's Q3 2026 print is the main quantitative datapoint in scope: orders up 7% reported and 10% organic, revenue down 3% reported and flat organically, adjusted EPS guidance cut to $5.40-$5.45 from $5.55-$5.70, and a divestiture-driven three-segment restructuring effective January 1, 2027. Most filings disclose no period-over-period financial data, so the enriched comparison fields are sparse across this batch; conclusions below rely primarily on governance and compensation disclosures. Several filings carry non-financial enriched data only, and where a classification is ambiguous (e.g., CCO Holdings, Charter preferred dividend) it has been flagged rather than forced.

38 high priority 38 total filings
· daily

US Executive Compensation Proxy SEC Filings — October 26, 2026

This Executive Compensation Insights digest covers 23 SEC DEF 14A proxy filings dated October 26, 2026, the large majority of which are procedural annual or special meeting notices rather than compensation disclosures. The most material developments cluster around Nasdaq and NYSE American listing-compliance pressure: XCF Global, Treasure Global, TScan Therapeutics, and AEON Biopharma are all seeking reverse stock split authority, and XCF faces a December 7, 2026 compliance deadline. A second theme is SPAC liquidity stress, with GP-Act III and Globa Terra both seeking deadline extensions that carry redemption and trust-dilution risk. Compensation-specific disclosures are limited to ScanSource (auditor change and pay-versus-performance tables), Espey Mfg. (CEO compensation actually paid rising from $651,079 in FY2024 to $934,073 in FY2026, roughly flat in FY2026 at +0.8%), and FactSet (multi-year NEO tables through fiscal 2026). Enriched period-over-period, insider, and capital-allocation fields are largely absent from the excerpts provided, so quantitative trend synthesis is constrained; the digest relies on the figures explicitly stated in each filing. Governance signals of note include concentrated dual-class control at Village Super Market and the reduced board size at Espey.

23 high priority 23 total filings
· daily

US Executive Officer Management Changes SEC — October 26, 2026

Across the 34 filings in this 2026-10-26 window, the dominant theme is executive and board turnover rather than financial performance: roughly two-thirds of the filings are board appointments, resignations, or officer transitions, and only a handful (Clearwater Paper, VerifyMe/OpenWorld, Xtend AI, Health In Tech) carry quantitative or enriched financial content. The most material developments are the LiveWire Group CEO resignation with a Chief Restructuring Officer appointment and a Special Restructuring Committee (signaling a possible financing, sale, or recapitalization), the Seres Therapeutics and Earth Science Tech CFO departures ahead of filing deadlines, and the OpenWorld/VerifyMe preliminary Q3 figures showing ~$10.0M GAAP loss against $6.9M-$7.2M revenue, driven by ~$11.9M non-recurring stock compensation. Clearwater Paper is the only filing with a true period-over-period comparison set: Q3 2026 net sales fell to $385M from $399M, the net loss narrowed to $2M from $53M (which included a $48M goodwill impairment), and nine-month Adjusted EBITDA fell to $18M from $87M. The CFO rotation chain (AutoZone to FedEx, with Jamere Jackson moving to FedEx on November 30 and AutoZone opening an external search) and the Mark Young interim CFO appointment at MasterBrand during its American Woodmark integration are the clearest sector-level finance-leadership churn signals. Insider and capital-allocation data are largely absent from these 8-Ks, so most conviction reads must be inferred from governance structure rather than disclosed trades.

34 high priority 34 total filings
· daily

US Corporate Board Director Changes SEC Filings — October 26, 2026

The stream covers 34 US SEC filings dated October 26, 2026, almost all of them 8-K Item 5.02 disclosures of officer, director, or board changes. Two dominant themes emerge: a cluster of CFO and senior-officer transitions (FedEx/AutoZone, MasterBrand, Seres, Clearwater-adjacent governance, NetScout COO, Earth Science Tech CFO, Xtend AI COO) and a steady flow of routine independent-director appointments that add board depth without changing financial trajectory. The most material developments are the LiveWire Group CEO exit with a Chief Restructuring Officer and special restructuring committee (signaling a possible financing, sale, or recapitalization), the Health In Tech founder-to-CEO handover tied to an existing Nasdaq compliance issue, and the VerifyMe/OpenWorld reverse-takeover preliminary Q3 results showing $6.9-7.2M revenue against a roughly $10.0M GAAP net loss. Several filings carry no period-over-period financial data, so trend analysis is limited to the Clearwater Paper Q3 results (net sales down to $385M from $399M, net loss narrowed to $2M from $53M, nine-month Adjusted EBITDA down to $18M from $87M) and the VerifyMe preliminary figures. Governance-quality concerns surfaced in Cycurion (director independence lapse tied to law-firm payments) and Gladstone's multi-entity Wilkinson resignation, while the FedEx CFO appointment and Nasdaq/Ekholm board addition read as positive credentialing. Sentiment is predominantly neutral, with negative and mixed tones concentrated in restructuring, abrupt executive exits, and preliminary loss disclosures.

34 high priority 34 total filings
· daily

US Executive Compensation Proxy SEC Filings — October 23, 2026

This digest covers 25 DEF 14A and DEFM14A filings dated around October 23, 2026, all within the stream's focus on executive compensation, governance, and shareholder proposals. The dominant theme is governance housekeeping and control structures: several filings reveal concentrated insider control (RAVE's Newcastle-affiliated Chairman at 22.9%, Atlantic American's controlled-company status, 1-800-Flowers' ten-vote Class B shares, Ubiquiti's combined CEO/Chairman), while others expose executive turnover (LIQTECH, Sky Quarry, Natural Alternatives CFO resignation, Marpai director non-renomination). Compensation disclosures show mixed pay trajectories: Flexsteel's CEO pay was flat (+0.4%) while its CGO rose 14.4%, and Mawson/Big Digital Energy showed sharply lower compensation actually paid to its PEO in 2025, with Rahul Mewawalla's CAP turning negative. A recurring microcap pattern emerges, with reverse-split authorizations appearing in OLB Group, Hoth/Rocket One, Tenaya, and Wheeler REIT, usually signaling Nasdaq listing-compliance pressure. The largest single event is the Blue Acquisition/Blockfusion SPAC merger ($450M consideration, mixed sentiment, unresolved financing), which carries the highest materiality in the set.

25 high priority 25 total filings
· daily

US Executive Officer Management Changes SEC — October 23, 2026

The 39 filings in this Officer and Director Change stream (all dated 2026-10-23 window) are dominated by governance housekeeping: routine director resignations, interim CFO and CAO appointments, and succession moves, most explicitly stated as not involving any disagreement with the company. The material exceptions are Lumen's Q3 2026 preliminary results and CEO appointment (LKQ, materiality 9/10) that withdrew full-year guidance and show a 5.4% parts and services organic decline with Europe down 9.8%, and Ardent Health's recharacterization of former CEO Bonick's separation as a for-Cause termination with about $4.5M of severance discontinued and PRSUs cancelled. Finance-function turnover is elevated, with CFO or principal accounting officer changes at Premier Air Charter, Offerpad, Methode Electronics and AB Commercial Real Estate Debt Fund, and two more executive exits (Acadia's head of R&D and Andersons' CHRO). Capital-related dilution and restructuring appear in Bio Essence, Tessera/BiomX and Reliance Global, while compensation is trending upward at Edesa Biotech (base salaries up roughly 75-84% retroactive to July 2026) and Freshpet. Governance is being refreshed through several independent-director additions (Vivid Seats, Fiserv, Civista, FS Bancorp) and multiple planned retirements in 2026-2027. Overall the market implication is limited for most names, with LKQ and Ardent the main items needing active attention.

39 high priority 39 total filings
· daily

US Corporate Board Director Changes SEC Filings — October 23, 2026

The 39 filings for the 'USA Board Room Changes' stream (all dated 2026-10-23 window) are overwhelmingly governance-focused: officer and director departures, interim appointments, severance and retention arrangements, and board refreshes. The most material event is LQR-style-free but clearly consequential: LKQ Corporation's preliminary Q3 2026 results (revenue $3.32B vs $3.50B, net loss of $16M-$32M including $111M impairments, adjusted EPS $0.47-$0.53 vs $0.84, Europe margin compressing to 4.1%-5.1% from 10.0%) combined with a CEO change to Salvatore Abbate effective December 15, 2026 and withdrawn full-year guidance. Insider and compensation signals are mixed: Ardent Health is recharacterizing a former CEO's exit as 'for Cause' and cancelling ~$4.5M of severance and PRSUs, while Edesa Biotech roughly doubled executive base salaries (+75% to +84%) retroactively. Several CFO and CAO transitions (Offerpad, Methode, Premier Air, AB Commercial Real Estate Fund) cluster around interim arrangements, a pattern that raises near-term reporting-continuity questions. Filings lacking quantitative financial data (most governance-only 8-Ks) were scored on governance significance rather than performance trends, so period-over-period comparisons are available for only a handful of companies.

39 high priority 39 total filings
· daily

US Executive Compensation Proxy SEC Filings — October 22, 2026

This Executive Compensation Insights digest covers 17 DEF 14A and DEFM14A filings dated October 22, 2026, and the stream is governance-focused, so most filings yield procedural rather than quantitative insight. The most material development is Personalis' merger with Tempus (materiality 9/10), where equity award treatment is disclosed but the per-share price is not in the excerpt, making the deal terms incomplete for valuation. Processa Pharmaceuticals' reverse split tied to its Vidya Therapeutics merger and $200M PIPE (materiality 8/10) carries heavy dilution, with legacy holders falling to about 1.4% of common stock. Several filings seek reverse split authority (LM Funding/PowerCompute, 20/20 Biolabs, Processa), a clear sector pattern among distressed or recapitalizing small caps. Financial distress is most visible at IGC Pharma, where operating loss widened to $7.7M from $6.0M and gross profit fell 36%, with net loss masked by non-cash other income. Compensation design themes include performance-based long-term incentives at Madison Square Garden Entertainment, and CEO performance awards and plan amendments at Copart and Aytu BioPharma. Most other filings are routine director elections and auditor ratifications with neutral sentiment.

17 high priority 17 total filings
· daily

US Executive Officer Management Changes SEC — October 22, 2026

The 50-filing batch for the USA Executive & Director Changes stream is dominated by governance housekeeping rather than market-moving events: at least 17 filings are the same Invesco fund-sponsor PFAO handover (Kelli Gallegos leave effective Oct 19, Lori Anello appointed effective Oct 22), which is administrative and carries no fund-level impact. The substantive filings are concentrated in a handful of CFO and CEO-level transitions (Kinsale CFO succession to Tangard on March 2, 2027; Forgent Power CFO change to Amy Ard; Comfort Systems CFO retirement with Julie Shaeff as successor; Plumas Bancorp CFO transition to Kelsey Cassinelli on January 1, 2027; Frequency Electronics CFO change to Allen Kaplan on November 1, 2026; Lineage CCO retirement on April 19, 2027). Several filings carry performance or strategic content beyond the personnel change: Deckers (record Q2 sales of $1.481B, but comparable DTC down 6.4% and FY27 EPS guidance raised to $7.80-$7.95 with a ~$0.52 tariff-refund benefit), Lindsay (Q4 revenue +5% YoY but full-year revenue down 6% to $635.9M and operating income down 24%), Ategrity (Q3 net income down 35.7% YoY despite a combined ratio improvement to 84.7%), and Fractyl Health (a 45% workforce cut and Rejuva wind-down alongside positive REMAIN-1 pivotal data). The most notable leadership-driven signal is Fractyl's co-founder Jay Caplan retiring effective October 30, 2026 in the middle of a restructuring. Among CEO-level developments, the Federal Home Loan Bank of New York CEO resignation with an interim CEO appointed is the most consequential governance event, while GBank's planned succession and Evercore's co-president structure are notable for continuity planning. Because the enriched period-over-period data is sparse for most governance filings, the cross-company picture is more about the density of CFO and CAO turnover and the uniformity of the Invesco handover than about measurable financial trends.

50 high priority 50 total filings